注射用尤瑞克林治疗急性脑梗死系统评价  

Systematic Review of Urinary Kallidinogenase Injection for Acute Ischemic Stroke

作　　者：王苹莉[1] 肖美娟[1] 叶祖森[1] 樊楷[1] 曹运刚[1] 耿媛媛[1] 郑荣远[1] 韩钊[1] 

机构地区：[1]温州医学院附属第一医院脑血管科,浙江温州325000

出　　处：《药物流行病学杂志》2010年第1期9-12,共4页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:系统评价注射用尤瑞克林能否改善急性脑梗死患者的神经功能缺损症状,促进其神经功能的恢复。方法:通过计算机检索、手工检索及向药厂索取资料,全面收集全世界范围内注射用尤瑞克林治疗急性脑梗死的随机对照试验(RCT),并按Cochrane协作网推荐的方法进行系统评价。结果:共纳入13个RCT(1437例患者),13个试验在治疗结束时进行了神经功能缺损评价,3个试验观察到严重不良反应。Meta分析结果显示,注射用尤瑞克林治疗组与对照组比较能显著改善神经功能缺损,差异有统计学意义[OR=2.55,95%CI(2.04,3.20)];3个试验的严重不良反应与血压相关。结论:注射用尤瑞克林有改善急性脑梗死患者神经功能缺损,但因研究质量及研究样本的局限性,尚需进行高质量、大样本的随机对照试验予以进一步证实。Objective： To determine whether urinary kallidinogenase injection could improve the situation of neurological deficit without causing harm in patients with acute Ischemic stroke. Method： The electronic bibliographic databases： Cochrane Central Register of Controlled Trials （CENTRAL, Issue 3, 2009） , MEDLINE （1996 to November 2009） , EMBASE （1984 to November 2009） and China Biological Medicine Database （1978 to November 2009） were searched. Handsearching-was also done to identify other published and unpublished data. The data were extracted and evaluated by two reviewers independently with a designed extraction form. The Cochrane Collaboration＇s RevMan 4.2 was used for the data analysis. Result： 13 randomized trials involving 1 437 patients were included. 13 trials neurological deficits were measured at the end of the treatment. 3 trials were reported to have their adverse events. The results of the Meta ana- lyses indicated that the urinary kallidinogenase injection was associated with a significant improvement in the neurological deficits （ OR 2.55, 95% CI 2.04 to 3.20）. Conclusion： The evidence currently available showed that the urinary kallidinogenase injection may reduce neurological deficits in patients with acute Ischemic stroke. However, because of the limitation of the trial quality and specimen, some higher quality trials are needed to prove it.

关 键 词：尤瑞克林/注射剂 脑梗死 随机对照试验 系统评价 META分析 

分 类 号：R743.3[医药卫生—神经病学与精神病学]